| Bioactivity | (S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia[1][2]. |
| Name | (S)-VQW-765 |
| Formula | C19H22N2O |
| Molar Mass | 294.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172(5):1292-304. [2]. Mazurov A, et al. Nicotinic acetylcholine receptor modulators[J]. Small Molecule Therapeutics for Schizophrenia, 2015: 213-253. |